- Home
- RDHL vs GRI Comparison
RDHL vs GRI Comparison
Compare RDHL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- GRI
- Stock Information
- Founded
- RDHL 2009
- GRI 2018
- Country
- RDHL Israel
- GRI United States
- Employees
- RDHL N/A
- GRI N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- GRI Health Care
- Exchange
- RDHL Nasdaq
- GRI Nasdaq
- Market Cap
- RDHL 6.8M
- GRI 5.6M
- IPO Year
- RDHL N/A
- GRI N/A
- Fundamental
- Price
- RDHL $4.76
- GRI $0.42
- Analyst Decision
- RDHL
- GRI Strong Buy
- Analyst Count
- RDHL 0
- GRI 2
- Target Price
- RDHL N/A
- GRI $11.50
- AVG Volume (30 Days)
- RDHL 9.0K
- GRI 181.8K
- Earning Date
- RDHL 04-07-2025
- GRI 03-27-2025
- Dividend Yield
- RDHL N/A
- GRI N/A
- EPS Growth
- RDHL N/A
- GRI N/A
- EPS
- RDHL N/A
- GRI N/A
- Revenue
- RDHL $3,707,000.00
- GRI N/A
- Revenue This Year
- RDHL $224.90
- GRI N/A
- Revenue Next Year
- RDHL $82.69
- GRI N/A
- P/E Ratio
- RDHL N/A
- GRI N/A
- Revenue Growth
- RDHL N/A
- GRI N/A
- 52 Week Low
- RDHL $4.76
- GRI $0.30
- 52 Week High
- RDHL $20.28
- GRI $12.31
- Technical
- Relative Strength Index (RSI)
- RDHL 26.11
- GRI 28.18
- Support Level
- RDHL $5.20
- GRI $0.43
- Resistance Level
- RDHL $5.50
- GRI $0.60
- Average True Range (ATR)
- RDHL 0.23
- GRI 0.06
- MACD
- RDHL -0.07
- GRI -0.00
- Stochastic Oscillator
- RDHL 0.00
- GRI 10.91
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.